Pharmaceuticals, Biotechnology and Life Sciences
Sandoz posts 7% revenue growth for 2025, driven by 15% biosimilars expansion, and guides for accelerated sales and margin growth in 2026.
The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). Approval of Tyruko by the European Medicines Agency is also expected imminently.
Sandoz has announced the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie’s COMBIGAN
Sandoz has announced the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
Sandoz has announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest…
Sandoz, a Novartis division, has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets,…
Sandoz Tuesday said it got approval from US Food and Drug Administration for its biosimilar Ziextenzo, which is in particularly significant since Sandoz short-acting filgrastim Zarxio is the first biosimilar to surpass its reference biologic in US market share.
Sandoz is resubmitting its Biologics License Application for a proposed biosimilar pegfilgrastim to the US FDA
Beximco Pharmaceuticals Limited will buy from Novartis’ Sandoz a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US…
Novartis’ Sandoz, received on Tuesday from the European Commission (EC) the marketing authorization for biosimilar Ziextenzo (pegfilgrastim), which is indicated to reduce the…